Vera Therapeutics, Inc. Other Accrued Liabilities, Current
Vera Therapeutics, Inc. (VERA) had Other Accrued Liabilities, Current of $2.73 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Other Accrued Liabilities, Current $2.73M.
- 2026-03-31: Other Accrued Liabilities, Current $3.47M.
- 2025-12-31: Other Accrued Liabilities, Current $1.92M; Other Accrued Liabilities, Current as first filed $1.37M.
- 2025-09-30: Other Accrued Liabilities, Current $3.69M.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.73M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $3.47M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.92M 10-Q · filed 2026-08-10 | $1.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.69M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $2.15M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.40M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $1.75M 10-K · filed 2026-02-26 | $1.04M 10-K · filed 2025-02-28 |
| 2024-09-30 | $1.43M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $820.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.11M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $563.00K 10-K · filed 2025-02-28 | $619.00K 10-K · filed 2024-03-27 |
| 2023-09-30 | $511.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $622.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $474.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $295.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $174.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $196.00K 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $598.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $627.00K 10-K · filed 2023-03-28 | $286.00K 10-K · filed 2022-03-28 |
| 2021-09-30 | $666.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $413.00K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $326.00K 10-Q · filed 2021-06-24 | |
| 2020-12-31 | $130.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |